{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:38:28Z","timestamp":1791581908560,"version":"4.3.4"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007659","name":"Bayer HealthCare Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ctrv.2024.102733","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T23:35:32Z","timestamp":1712187332000},"page":"102733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["NTRK gene fusion testing and management in lung cancer"],"prefix":"10.1016","volume":"127","author":[{"given":"Matteo","family":"Repetto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Chiara Garassino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert H.","family":"Loong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Lopez-Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Planchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin R.","family":"Rudzinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Drilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caicun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2024.102733_b0005","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2021.09.005","article-title":"NTRK fusions in lung cancer: from biology to therapy","volume":"161","author":"Harada","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2024.102733_b0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11864-020-00741-z","article-title":"TRK inhibitors in non-small cell lung cancer","volume":"21","author":"Harada","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0015","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.3390\/ijms23126748","article-title":"NSCLC as the paradigm of precision medicine at its finest: the rise of new druggable molecular targets for advanced disease","volume":"23","author":"Michelotti","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2024.102733_b0020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11912-019-0770-x","article-title":"Emerging targeted therapies for the treatment of non-small cell lung cancer","volume":"21","author":"Halliday","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ctrv.2024.102733_b0025","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/17476348.2020.1714441","article-title":"Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives","volume":"14","author":"Genova","year":"2020","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.ctrv.2024.102733_b0030","first-page":"255","article-title":"Routine molecular pathology diagnostics in precision oncology","volume":"118","author":"Wenzel","year":"2021","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.ctrv.2024.102733_b0035","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/cam4.4459","article-title":"Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: results of a survey of U.S. oncologists","volume":"11","author":"Mileham","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2024.102733_b0040","article-title":"Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer","author":"Amatu","year":"2019305","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0045","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/annonc\/mdz204","article-title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","volume":"30","author":"Marchio","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0050","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1593\/tlo.08127","article-title":"TRK-A, HER-2\/neu, and KIT expression\/activation profiles in salivary gland carcinoma","volume":"1","author":"Negri","year":"2008","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0055","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1349-7006.2007.00722.x","article-title":"Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer","volume":"99","author":"Yu","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2024.102733_b0060","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF02706217","article-title":"Expression of the neurotrophin receptors trk a and trk B in adult human astrocytoma and glioblastoma","volume":"28","author":"Wadhwa","year":"2003","journal-title":"J Biosci"},{"key":"10.1016\/j.ctrv.2024.102733_b0065","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0070","article-title":"Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion","volume":"2018","author":"Farago","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0075","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920975613","article-title":"A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors","volume":"12","author":"Forsythe","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0080","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41379-019-0324-7","article-title":"NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls","volume":"33","author":"Solomon","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2024.102733_b0085","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41698-021-00206-y","article-title":"Genomic context of NTRK1\/2\/3 fusion-positive tumours from a large real-world population","volume":"5","author":"Westphalen","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0090","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/2159-8290.CD-14-0765","article-title":"TRKing down an old oncogene in a new era of targeted therapy","volume":"5","author":"Vaishnavi","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2024.102733_b0095","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1158\/1078-0432.CCR-19-3165","article-title":"TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations","volume":"26","author":"Rosen","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102733_b0100","article-title":"Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project","volume":"33","author":"Bridgewater","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.ctrv.2024.102733_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041416","article-title":"Brain metastases in lung cancers with emerging targetable fusion drivers","volume":"21","author":"Tan","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2024.102733_b0110","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10555-015-9592-y","article-title":"Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?","volume":"34","author":"Toyokawa","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ctrv.2024.102733_b0115","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jtho.2018.07.001","article-title":"The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib","volume":"13","author":"Patil","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0120","article-title":"Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer. JCO Precis","volume":"2017","author":"Gainor","year":"2017","journal-title":"Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23062916","article-title":"The challenge and opportunity of NTRK inhibitors in non-small cell lung cancer","volume":"23","author":"Qin","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2024.102733_b0130","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdy539","article-title":"Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study","volume":"30","author":"Hong","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0135","doi-asserted-by":"crossref","first-page":"e01054","DOI":"10.1002\/rcr2.1054","article-title":"Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR-mutant NSCLC patient with acquired LMNA-NTRK1 fusion following osimertinib resistance","volume":"10","author":"Wang","year":"2022","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.ctrv.2024.102733_b0140","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cllc.2019.09.004","article-title":"Evidence of NTRK1 fusion as resistance mechanism to EGFR TKI in EGFR+ NSCLC: results from a large-scale survey of NTRK1 fusions in chinese patients with lung cancer","volume":"21","author":"Xia","year":"2020","journal-title":"Clin Lung Cancer"},{"issue":"518\u201330","key":"10.1016\/j.ctrv.2024.102733_b0145","first-page":"e7","article-title":"Cell-free DNA next-generation sequencing prediction of response and resistance to third-generation EGFR inhibitor","volume":"19","author":"Helman","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2024.102733_b0150","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2024.102733_b0155","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/1759-7714.13817","article-title":"ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non-small cell lung cancer","volume":"12","author":"Hou","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ctrv.2024.102733_b0160","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s12253-019-00685-2","article-title":"Methods for identifying patients with tropomyosin receptor kinase (TRK) fusion cancer","volume":"26","author":"Wong","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.ctrv.2024.102733_b0165","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jmoldx.2019.03.008","article-title":"Detection of tumor NTRK gene fusions to identify patients who may benefit from tyrosine kinase (TRK) inhibitor therapy","volume":"21","author":"Hsiao","year":"2019","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ctrv.2024.102733_b0170","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41416-021-01536-1","article-title":"NTRK1 fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types","volume":"126","author":"Rolfo","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2024.102733_b0175","article-title":"Efficient identification of patients with NTRK fusions using a supervised tumor-agnostic approach","author":"Hernandez","year":"2023","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ctrv.2024.102733_b0180","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2016.70.7539","article-title":"Clinical and technical aspects of genomic diagnostics for precision oncology","volume":"35","author":"Sheikine","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0185","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jmoldx.2021.09.008","article-title":"Evaluating targeted next-generation sequencing assays and reference materials for NTRK fusion detection","volume":"24","author":"Bormann Chung","year":"2022","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ctrv.2024.102733_b0190","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.annonc.2020.11.021","article-title":"ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research","volume":"32","author":"Belli","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0195","first-page":"12","article-title":"Target enrichment approaches for next-generation sequencing applications in oncology","author":"Singh","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ctrv.2024.102733_b0200","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41379-021-00913-8","article-title":"NTRK insights: best practices for pathologists","volume":"35","author":"Hechtman","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2024.102733_b0205","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1111\/1759-7714.14644","article-title":"Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China","volume":"13","author":"Xu","year":"2022","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ctrv.2024.102733_b0210","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0215","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/1878-0261.13214","article-title":"Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib","volume":"16","author":"Dziadziuszko","year":"2022","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0220","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/0008-5472.CAN-19-0372","article-title":"Detection of NTRK fusions: merits and limitations of current diagnostic platforms","volume":"79","author":"Solomon","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102733_b0225","article-title":"Getting your laboratory on track with neurotrophic receptor tyrosine kinase","author":"Rudolf Eyerer","year":"2022","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ctrv.2024.102733_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100346","article-title":"Pan-TRK immunohistochemistry to optimize the detection of NTRK fusions: removing the hay when looking for the needle","volume":"36","author":"Conde","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2024.102733_b0235","article-title":"Canadian multicentric pan-TRK (CANTRK) immunohistochemistry harmonization dtudy","volume":"37","author":"Hyrcza","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2024.102733_b0240","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.5858\/arpa.2020-0400-RA","article-title":"Pan-TRK immunohistochemistry: an example-based practical approach to efficiently identify patients with NTRK fusion cancer","volume":"145","author":"Conde","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ctrv.2024.102733_b0245","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semcancer.2020.07.009","article-title":"Precision medicine in non-small cell lung cancer: current applications and future directions","volume":"84","author":"Yang","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.ctrv.2024.102733_b0250","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s12094-021-02558-0","article-title":"Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours","volume":"23","author":"Garrido","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0255","doi-asserted-by":"crossref","first-page":"176","DOI":"10.21147\/j.issn.1000-9604.2022.03.03","article-title":"Health Commission Of The People\u2019s Republic Of China N. National guidelines for diagnosis and treatment of lung cancer 2022 in China (English version)","volume":"34","year":"2022","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102733_b0260","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3390\/curroncol28010053","article-title":"Canadian consensus for biomarker testing and treatment of TRK fusion cancer in adults","volume":"28","author":"Bebb","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0265","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical Practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0270","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO clinical Practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0275","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in Resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102733_b0280","unstructured":"ClinicalTrials.gov. A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer. 2024. Updated March 15, 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT04302025. Accessed 18 March 2024."},{"key":"10.1016\/j.ctrv.2024.102733_b0285","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.annonc.2020.03.299","article-title":"JSCO\u2014ESMO\u2014ASCO\u2014JSMO\u2014TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions","volume":"31","author":"Yoshino","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0290","first-page":"OP2200611","article-title":"Compromised outcomes in stage IV non-small-cell lung cancer with actionable mutations initially treated without tyrosine kinase inhibitors: a retrospective analysis of real-world data","author":"Scott","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.ctrv.2024.102733_b0295","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/annonc\/mdz077","article-title":"Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib","volume":"30","author":"Schoenfeld","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0300","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.953013","article-title":"Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020","volume":"12","author":"Kooijman","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0305","unstructured":"Bayer HealthCare Pharmaceuticals Inc. VITRAKVI prescribing information. 2022. Updated 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/210861s008lbl.pdf. Accessed 13 September 2023."},{"key":"10.1016\/j.ctrv.2024.102733_b0310","first-page":"9056","article-title":"Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer","volume":"41","author":"Lin","year":"2023","journal-title":"ASCO 2023 Annual Meeting"},{"key":"10.1016\/j.ctrv.2024.102733_b0315","unstructured":"Genentech I. ROZLYTREK (entrectinib) prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/212725Orig1s009lbl.pdf. Accessed 4 December 2023."},{"issue":"41","key":"10.1016\/j.ctrv.2024.102733_b0320","first-page":"9047","article-title":"Updated efficacy and safety of entrectinib in patients (pts) with locally advanced\/metastatic NTRK fusion-positive (fp) non-small cell lung cancer (NSCLC)","volume":"2023","author":"Cho","year":"2023","journal-title":"ASCO Annual Meeting"},{"key":"10.1016\/j.ctrv.2024.102733_b0325","doi-asserted-by":"crossref","first-page":"viii23","DOI":"10.1093\/annonc\/mdz282","article-title":"TRK inhibitors in TRK fusion-positive cancers","volume":"30","author":"Drilon","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0330","doi-asserted-by":"crossref","first-page":"e2100418","DOI":"10.1200\/PO.21.00418","article-title":"Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive lung cancers","volume":"6","author":"Drilon","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0335","article-title":"1288P efficacy of entrectinib in patients with NTRK or ROS1 fusionpositive NSCLC with CNS metastases at baseline","volume":"31","author":"Dziadziuszko","year":"2020","journal-title":"ESMO"},{"key":"10.1016\/j.ctrv.2024.102733_b0340","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0345","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102733_b0350","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.annonc.2020.05.006","article-title":"Characterization of on-target adverse events caused by TRK inhibitor therapy","volume":"31","author":"Liu","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0355","doi-asserted-by":"crossref","first-page":"10471","DOI":"10.1007\/s00520-022-07401-y","article-title":"Management of adverse events related to first-generation tyrosine receptor kinase inhibitors in adults: a narrative review","volume":"30","author":"Martineau","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2024.102733_b0360","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent- front mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2024.102733_b0365","unstructured":"Turning Point Therapeutics. Turning Point Therapeutics granted breakthrough therapy designation for repotrectinib treatment in patients with NTRK-positive, TKI-pretreated advanced solid tumors. 2021. Updated October 4, 2021. https:\/\/www.globenewswire.com\/news-release\/2021\/10\/04\/2307947\/0\/en\/Turning-Point-Therapeutics-Granted-Breakthrough-Therapy-Designation-for-Repotrectinib-Treatment-in-Patients-with-NTRK-Positive-TKI-Pretreated-Advanced-Solid-Tumors.html. Accessed 17 May 2023."},{"key":"10.1016\/j.ctrv.2024.102733_b0370","unstructured":"Innovent Biologics. Innovent announces first patient dosed in the phase II basket trial of taletrectinib for solid tumors with NTRK fusion. 2021. Updated June 18, 2021. https:\/\/www.innoventbio.com\/InvestorsAndMedia\/PressReleaseDetail?key=256. Accessed 17 May 2023."},{"key":"10.1016\/j.ctrv.2024.102733_b0375","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1038\/s41467-019-11496-z","article-title":"The new-generation selective ROS1\/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models","volume":"10","author":"Katayama","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2024.102733_b0380","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e21663","article-title":"Preclinical evaluation of SIM1803-1A, a small molecule Trk\/ROS1 dual inhibitor for wild and mutate NTRK\/ROS1 fusion solid malignancies","volume":"38","author":"Wang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0385","first-page":"79","article-title":"Abstract 2198: PBI-200: a novel, brain penetrant, next generation pan-TRK kinase inhibitor","volume":"2019","author":"Regina","year":"2019","journal-title":"American Association for Cancer Research Annual Meeting"},{"key":"10.1016\/j.ctrv.2024.102733_b0390","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41591-019-0542-z","article-title":"Resistance to TRK inhibition mediated by convergent MAPK pathway activation","volume":"25","author":"Cocco","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2024.102733_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103564","article-title":"Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib","volume":"169","author":"Awada","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2024.102733_b0400","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/ajco.13727","article-title":"Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: consensus of a Singapore task force","volume":"18","author":"Lim","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0405","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10147-019-01610-y","volume":"25","author":"Naito","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0410","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3390\/curroncol28010038","article-title":"Canadian consensus for biomarker testing and treatment of TRK fusion cancer in pediatric patients","volume":"28","author":"Perreault","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0415","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cancergen.2021.11.006","article-title":"Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib","volume":"260\u2013261","author":"Rudzinski","year":"2022","journal-title":"Cancer Genet"},{"key":"10.1016\/j.ctrv.2024.102733_b0420","doi-asserted-by":"crossref","first-page":"e2200692","DOI":"10.1200\/PO.22.00692","article-title":"Real-world experience with neurotrophic tyrosine receptor kinase fusion-positive tumors and tropomyosin receptor kinase inhibitors in veterans","volume":"7","author":"Zhou","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2024.102733_b0425","doi-asserted-by":"crossref","first-page":"21168","DOI":"10.1038\/s41598-023-48613-4","article-title":"Detection of NTRK fusions by RNA-based nCounter is a feasible diagnostic methodology in a real-world scenario for non-small cell lung cancer assessment","volume":"13","author":"de Oliveira","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2024.102733_b0430","unstructured":"Genentech. ROZLYTREK summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rozlytrek-epar-product-information_en.pdf. Accessed 23 December 2022."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224000604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224000604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T17:45:48Z","timestamp":1716399948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224000604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":86,"alternative-id":["S0305737224000604"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102733","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NTRK gene fusion testing and management in lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102733"}}